热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　宜明昂科-B（01541）早盘上涨7.18%，现报5.82港元，成交额2903.22万港元。

　　3月6日，宜明昂科-B发布公告，集团已获中华人民共和国国家药品监督管理局（国家药监局）批准进行IMM01（替达派西普）联合IMM2510（珀维拉芙普α），另加化疗或不加化疗用于治疗晚期恶性肿瘤的临床试验。这一重大进展标志着公司在快速推进IMM01（替达派西普）及IMM2510（珀维拉芙普α）的临床研究方面又迈出了关键一步。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.